University of Minnesota. Driven to Discover.
Admission to an Ebola treatment unit was tied to a 38% drop in secondary cases.
Four of the 7 new cases were reported in Katwa, the latest outbreak hot spot.
Also, the NIAID has reached an agreement to license an experimental treatment.
The drug, zoliflodacin, was highly effective in treating urogenital and rectal infections but not pharyngeal cases.
Immune response lasted 2.5 years for the vaccines, the longest yet in ongoing studies of Ebola immunization.
Bacillus could be a tool to decolonize patients found to carry S aureus in their nose or intestines.
In another new development, the NIH today announced the start of the first human trial of a live attenuated vaccine against Zika.
The announcement comes as Nigeria is experiencing its largest outbreak, with 481 confirmed cases reported as of last week, 133 of them fatal.
As a commentary sounds the alarm, Lyme-carrying ticks spread into a new area in Tennessee.
On World Malaria Day, global health leaders aired concerns about stalled progress in some regions and recommitted to the battle against the disease.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.